Novo Nordisk must up its bid to take over Belgian biotech Ablynx, after the company’s largest shareholder reportedly said its 2.6 billion euro ($3.18 billion) offer was too low.

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on ...

Kidney transplantation from donors with HIV appeared to be noninferior to donors without HIV in terms of safety for ...

During the COVID pandemic, many of us have received multiple mRNA vaccines. New work by researchers at the VIB-UGent Center for Inflammation Research, Ghent University, and University Hospital Ghent, ...

Finally, Ablynx has entered ALX-0081 into development for the treatment of coronary syndromes, the first dromedary-derived V HH molecule in clinical development. MAbs have historically been ...

Thus, Ghent, Belgium–based Ablynx is developing a class of antibody fragment based on a single variable domain, a hinge region and two constant domains (CH2 and CH3) derived from llama antibodies.

Xaira Therapeutics today announced the appointment of Dr. Debbie Law and Julia Tran to its C-suite. Law will serve as chief ...